Table 1.
Ongoing trials regarding ICI + PARPi in ovarian cancer.
| Clinical trial identifier | Phase | Agents | Design | Status | Outcome |
|---|---|---|---|---|---|
| NCT02571725 | Phase I | Tremelimumab + Olaparib | BRCAm ROC | Results published | No DLT or grade 3 AE ORR 100% |
| NCT02484404 | Phase II | Durvalumab + Olaparib | Platinum-resistant ROC | Results published | ORR 14% Acceptable toxicity |
| TOPACIO NCT02657889 | Phase II | Pembrolizumab + Niraparib | Platinum-resistant ROC | Results published | ORR 18% PFS 3.4 months Acceptable toxicity |
| MEDIOLA NCT02734004 | Phase II | Durvalumab + Olaparib | BRCAm platinum-sensitive OC | Results published | ORR 63% Acceptable toxicity |
| NCT04034927 | Phase II | Tremetinib + Niraparib | Platinum-sensitive advanced OC | Recruiting | |
| KEYLYNK-001 NCT03740165 | Phase II | Pembrolizumab + Niraparib | BRCAwt advanced OC | Recruiting | |
| NCT02484404 | Phase I-II | Durvalumab + Niraparib | Advanced, recurrent, or metastatic ovarian, triple negative breast, lung, prostate, colorectal carcinoma or solid tumors | Recruiting | |
| DUO-O NCT03737643 | Phase III | Durvalumab + Niraparib | Advanced OC | Recruiting | |
| GUIDE2REPAIR NCT04169841 | Phase II | Durvalumab + Tremelimumab + Niraparib | HRR-mutated advanced or metastatic solid tumors | Not yet recruiting | |
| NCT02953457 | Phase I-II | Durvalumab + Tremelimumab + Niraparib | DDR-mutated recurrent or refractory OC | Recruiting | |
| FIRST NCT03602859 | Phase III | Durvalumab + Niraparib | Stage III or IV non-mucinous OC | Recruiting | |
| MOONSTONE NCT03955471 | Phase II | Dostarlimab + Niraparib | Advanced platinum-resistant OC | Recruiting | |
| NCT03806049 | Phase III | Dostarlimab + Niraparib | Advanced or recurrent platinum-sensitive OC | Not yet recruiting | |
| NCT03695380 | Phase I | Atezolizumab + Niraparib | Advanced OC | Recruiting | |
| ANITA NCT03598270 | Phase III | Atezolizumab + Niraparib | Recurrent OC | Recruiting | |
| JAVELIN NCT03642132 | Phase III | Avelumab + Niraparib | Advanced OC | Not recruiting | |
| NCT02873962 | Phase II | Nivolumab + Rucaparib | Relapsed OC | Recruiting | |
| ATHENA NCT03522246 | Phase III | Nivolumab + Rucaparib | Advanced OC | Recruiting | |
| ARIES NCT03824704 | Phase II | Nivolumab + Rucaparib | Platinum treated advanced OC | Recruiting | |
| NCT03101280 | Phase I | Atezolizumab + Rucaparib | Advanced or metastatic platinum-sensitive ovarian or endometrial cancer or triple negative breast cancer | Not recruiting | |
| NITCHE NCT04679064 | Phase II | Dostarlimab + Niraparib | Recurrent resistant OC not fit for platinum | Recruiting |